<DOC>
	<DOC>NCT00680654</DOC>
	<brief_summary>This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of BAY63-2521 in patients with pulmonary hypertension and stable treatment of sildenafil 20 mg.</brief_summary>
	<brief_title>Interaction Study in Patients With Pulmonary Hypertension and Stable Treatment of Sildenafil 20 mg TID</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Patients with pulmonary hypertension stable for the last 6 weeks Treated with Sildenafil 3 Ã— 20 mg Undergoing routine invasive diagnostics. Preexisting lung disease other than pulmonary arterial hypertension, Acute or severe chronic left heart failure, Severe coronary artery disease, Uncontrolled arterial hypertension; Congenital or acquired valvular or myocardial disease except acquired tricuspid valve insufficiency due to pulmonary hypertension, Systolic blood pressure &lt; 100 mmHg, heart rate &lt; 55 bpm or &gt;105 bpm, PaO2/FiO2 &lt; 50 mmHg, PaCO2 &gt; 55 mmHg, Severe hepatic insufficiency, Severe renal insufficiency, Administration of strong CYP3A4 inhibitors or inductors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Pulmonary hypertension</keyword>
</DOC>